InnoPharmax Inc.

InnoPharmax Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for oncology and other specialized disease areas. The company's primary function is to address unmet medical needs by creating advanced pharmaceutical products, ranging from anti-infection agents and immunological drugs to treatments for rare diseases and cancer. InnoPharmax leverages internally developed drug delivery platforms, such as OralPAS and MUCR, to enhance the safety and efficacy of its medicines, with a portfolio that includes both proprietary drugs and generics. Key offerings cover a broad spectrum: oral insulin for diabetes management, oncology agents like Innomustine, medications for infectious and rare diseases, as well as contrast agents for diagnostic imaging. InnoPharmax is also advancing pipeline products targeting conditions such as hypertension, heart failure, and Parkinson’s disease, reflecting a commitment to both innovation and therapeutic breadth. Founded in 2005 and headquartered in Taipei, the company plays a significant role in Taiwan’s healthcare market by providing high-quality, cost-effective pharmaceuticals, supported by ongoing research, unique formulation techniques, and global partnerships.